Scientists can now search, understand and act on complex R&D data in natural language by leveraging leading LLM capabilities within the Signals One platform Governed data and ontology-driven ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Delivers the only FDA-cleared ChLIA testosterone testing portfolio with direct measurement of total testosterone, free testosterone, and sex hormone-binding globulin Simplifies clinical workflow on a ...

"Revvity delivered strong first quarter results with 3% total company organic growth" and "Our adjusted operating margins came in at 23.6%, which was above our 23% outlook," said (CEO, President & ...

Shares of Revvity Inc. RVTY slid 3.70% to $83.90 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling 1.67% to 6,368.85 and Dow ...

Shares of Revvity Inc. RVTY slid 5.43% to $84.76 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index SPX falling 1.52% to 6,672.62 and Dow ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Revvity, Inc. announced the launch of multiple new discovery platforms and technologies at SLAS2026, which are designed to accelerate high-throughput drug discovery workflows. Making their debut at ...

(MENAFN- EIN Presswire) EINPresswire/ -- The global Molecular Cytogenetics Market is witnessing strong and sustained growth as precision diagnostics, oncology research, and genetic disorder screening ...

Revvity's diagnostics unit, which provides testing tools for processes such as genetic screening, was a standout performer ‍in the quarter ended December 28, notching 7% organic growth and revenue of ...

Revvity exceeded EPS and revenue expectations for Q4 2025. Stock price fell 7.89% in pre-market trading despite earnings beat. Company launched new AI services and acquired ACD/Labs. Operating margins ...